MedTrace Logo

Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine

NCT07416656 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-06-25

No results posted yet for this study

Summary

The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.

This may lead to underdiagnosis of diabetes in patients who develop diabetes during sulfasalazine treatment, and to undertreatment in patients with known diabetes due to falsely reassuring HbA1c values.

The study aims to answer two main questions:

1. How many patients treated with sulfasalazine have undiagnosed diabetes despite having HbA1c values below the diagnostic threshold?
2. Does HbA1c underestimate actual glucose levels when compared with continuous glucose monitoring (CGM) in patients with sulfasalazine-treated inflammatory arthritis, both in those with known diabetes and those that are not diagnosed with diabetes but have borderline HbA1c values (≥ 38 mmol/mol)?

Conditions

Sponsors & Collaborators

  • Klavs Würgler Hansen

    lead OTHER

Principal Investigators

  • Klavs W Hansen, Clinical Professor · Medicial Diagnostic Center, Silkeborg Regional Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416656 on ClinicalTrials.gov